Chimeric antigen receptor-modified T cells for acute lymphoid leukemia - Wikidata - awgldk - TriplyDB

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

http://www.wikidata.org/entity/Q29620130

about

Evolutionary dynamics of cancer in response to targeted combination therapy Clinical development of gene therapy: results and lessons from recent successes The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy Targeting the latent reservoir to achieve functional HIV cure Clinical manufacturing of CAR T cells: foundation of a promising therapy Adoptive immunotherapy against ovarian cancer CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Molecular therapeutics in pancreas cancer Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials A primer on tumour immunology and prostate cancer immunotherapy Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Novel technologies and emerging biomarkers for personalized cancer immunotherapy Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Cellular senescence in aging and age-related disease: from mechanisms to therapy The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Tailoring the Treatment of Melanoma: Implications for Personalized Medicine A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers Novel immunotherapies in lymphoid malignancies Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy Adoptive T-Cell Immunotherapy Lymphoma Immunotherapy: Current Status CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Potentiality of immunotherapy against hepatocellular carcinoma Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Immune Modulation in Hematologic Malignancies Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street Current practices and reform proposals for the regulation of advanced medicinal products in Canada The past, present and future of immunotherapy against tumor Adoptive T-cell therapy for cancer: The era of engineered T cells CAR T Cell Therapy: A Game Changer in Cancer Treatment B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look CAR T cells for solid tumors: armed and ready to go?Biomarkers for glioma immunotherapy: the next generation

P2860

Q21128788-4C756CD2-4104-4195-9732-F1C4D8263E2B Q26743393-2E517CCF-AA77-46A7-9691-23266B9A5DDD Q26744280-C12259C6-5BC3-44CE-9561-12B00CC572C9 Q26744654-52DF7EDC-6D61-4D9D-897C-89A620F9400A Q26745923-3DFF614B-667F-4C76-9351-69FBCB156361 Q26747037-ECA252AD-CEFC-4535-8FB4-47E81A7C74CC Q26748905-35B4CAC2-64CD-48C4-9194-A29CBC0724BB Q26749139-FB47CE6C-34F8-4AFC-8C48-0C1555D400DF Q26751709-740C2DF0-4AB3-4AC8-9F1D-1212AFD0E28B Q26764903-C630B923-38C5-4341-8F52-E64A556FA21E Q26765115-A66E2A7F-3AD0-4744-B3DA-E3F4A548AEF5 Q26765697-68A491FB-B064-4CD9-B9D8-E7494001AAE5 Q26767514-77EB3AED-D6D2-4B1C-BE77-034F95EC1093 Q26768154-FA2DC94F-3B0F-4508-9C50-8587CC957D66 Q26770391-E2BEBDB0-B834-4AF1-B12B-96C18A2E9592 Q26770780-BD882EFF-437E-4F96-B747-315E82AF1ECF Q26773309-37BABCA2-7E5A-4AFB-B88D-9E1439C59E91 Q26773500-4C8BE29C-E2D1-41C9-B1E9-4827D88CFD16 Q26774678-94D5AFC7-8924-4C89-8329-D3A150E87F78 Q26775720-71DF3E2E-7EE9-45BD-B23A-BB68897CEEA8 Q26775806-CEC07EDA-A411-42CE-9D72-585123777492 Q26777111-A913A468-DEDD-41FA-B9C8-180159BE6268 Q26777394-11D14D0D-7F26-49B2-9EA3-13C695453313 Q26778759-A17E1016-EB2F-4B6B-B4D2-B9895517C958 Q26779938-2CD584AB-7CEF-4D77-9925-14A612B1ABEE Q26782845-BF581C5A-2220-49CF-A02E-495A64E398B5 Q26782902-F5832D11-7058-47CF-A698-117076DC532F Q26783433-B0A14A0F-8DE9-4767-BA21-10D1F7485616 Q26784228-C3B3C291-E26B-4263-840B-45C28FC1146F Q26795540-F1B9E060-B99C-4F70-8EA8-1760154E203D Q26796307-A1099455-4B8F-45D8-9414-4221CB882442 Q26796314-73AB49ED-84FF-4F3F-B412-CB5CCE5EA8F3 Q26799357-F6BDAD8C-87F5-4BAE-B783-7F60F1588445 Q26799720-7EB7C15B-4C1A-4F5A-A768-06B673279CF8 Q26799896-2E020CEA-0705-4353-B087-854F27C26453 Q26800611-AB089D23-B727-42C8-A588-389475CC3A5B Q26822769-5997F932-F3F8-4890-927C-A2F9248CD6DF Q26824446-E800C69A-4A49-45D3-89DB-CCD521BFD688 Q26825489-166D992A-45E2-4883-82D8-67C6ED276F89 Q26825496-FF10F340-2904-43DD-8C83-A1D514FC0E78

P2860

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

http://www.wikidata.org/entity/Q29620130

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@en

type

label

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@en

prefLabel

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@ast

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@en

P1433

Q29620130-84DE8739-46BD-4FD7-B94E-D185D6C73FBE

P1476

Q29620130-615A18F6-3EAA-405A-A6F6-2EADF18C4A30

P2093

Q29620130-020C156B-45E9-4513-81B8-2162456B6928

Q29620130-234B6188-FF35-4A6A-9F64-EEB3CEE50102

Q29620130-5D05B136-A67F-4AAD-BADE-ABF1E58DE036

Q29620130-74FADDCD-6547-47C1-9BAF-ECC5291DCE47

Q29620130-80135BCC-6F31-4A89-BFD5-22F8F1B6A395

Q29620130-81E7D793-81E5-4EB9-9DAB-0F334D66DF0B

Q29620130-8EB5107B-2CCE-4369-9440-40CC9F4A848A

Q29620130-919A76BF-136A-41E9-A4C6-7A94D49719FC

Q29620130-9405583F-6F8E-4B66-9714-8CF0ADE25803

Q29620130-95E0096C-DBB8-4CC2-BFAC-9D9A2ED80A70

P2860

Q29620130-0B566251-E0CB-4F35-808D-AF98852DA9BA

Q29620130-12B95E78-9BC2-4F95-B440-60DB70FEE4A5

Q29620130-1E33559A-FE69-4FAE-ABDE-B4DAD2E7F45C

Q29620130-24584D59-D4FC-4B2A-B5A7-4D81D1EFC31F

Q29620130-2D49D2AE-B06B-47D3-95C8-5D50E04B31EC

Q29620130-2FC4813F-DA07-454A-86AC-D48F35700F80

Q29620130-4A1CECDB-C70F-4CF9-9F00-89425FE1EB61

Q29620130-59075A80-5924-4BFF-B229-B4DFEDEDA60B

Q29620130-590E4B46-842D-43C8-A8AC-24A4FB1CA5D1

Q29620130-6BC1BDD9-5A4F-40FA-BA3C-C847BFBD5FCD

P304

Q29620130-9CCC5139-E60F-4F3A-84DC-7BF5633854FE

P31

Q29620130-BC8125F1-9BDE-4DAC-B8A9-0ECA8D1E6823

P3181

Q29620130-155DA2D6-5BF5-42AC-8179-97F56A3F557E

P356

Q29620130-54629000-2A19-4135-93A2-02060ED8BCB4

P407

Q29620130-457688CF-34E6-46CA-A3FF-91F425011743

P433

Q29620130-B7285414-337C-4BD9-B75E-661343C98F65

P478

Q29620130-AD3BE7E4-E876-45C5-903D-C2929EB59F58

P50

Q29620130-E9F58373-A349-415B-93B2-BC0087C0822F

P577

Q29620130-F070776B-AAF8-49C1-8C63-E7CC2C3B5D71

P698

Q29620130-DAE47552-53A0-4C3A-BF7F-C37F08CF2E6D

P921

Q29620130-2211EB6B-DD04-4BA2-B95E-992AA4744A4B

P932

Q29620130-82C952FE-F54A-4A02-AE87-1EA21902A807

P3181

P356

P1433

The New England Journal of Medicine

P1476

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

@en

P2093

Anne Chew

http://www.w3.org/2001/XMLSchema#string

Bernd Hauck

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

David Barrett

http://www.w3.org/2001/XMLSchema#string

David L Porter

http://www.w3.org/2001/XMLSchema#string

J Fraser Wright

http://www.w3.org/2001/XMLSchema#string

Michael C Milone

http://www.w3.org/2001/XMLSchema#string

Michael Kalos

http://www.w3.org/2001/XMLSchema#string

Richard Aplenc

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Salvage therapy for refractory or relapsed acute lymphocytic leukemia.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

P304

1509-1518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

30828

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1215134

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P50

David T Teachey

P577

2013-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23527958

http://www.w3.org/2001/XMLSchema#string

P921

P932

4058440

http://www.w3.org/2001/XMLSchema#string